News at CenExel

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours - ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to...

CenExel Clinical Research Acquires CITrials

Salt Lake City, Mar. 9, 2021 /PRNewswire/ — CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of CITrials, a southern California-based clinical research firm with three sites serving Los Angeles, Orange, and Riverside/San Bernardino counties....

First-In-Human Study of OTO-413

A First-In-Human Study of OTO-413, an Intratympanic Sustained-Exposure Formulation of BDNF, for the Treatment of Speech-in-Noise Hearing Impairment Jeffery J. Anderson(1), James Robinson(1), Alice Blaj(1), Ines Hoffmann(1), Alan Foster(1), Justin Gull(2), Peter...

Translate »